

Company Profile

Wright Medical Group N.V. is a global medical device company focused on Extremities and Biologics. We are committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and are a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. For more information about Wright, visit www.wright.com.

Business Overview



Business

- Extremities and Biologics

Market Size/Growth

- Size: ~\$3.5B⁽¹⁾
- Growth: ~8-10%

Our Position

- Recognized Leader in Lower Extremities, Upper Extremities and Biologics

(1) 2014 iData Research Inc., 2013 Millennium Research Group, 2012 Life Science Intelligence, Management Estimates

High-Growth Extremities/Biologics Pure Play



Wright Medical At-A-Glance

Orthopaedic Medical Device Company Global

2017 Net Sales \$745M


2018E Net Sales \$806M⁽¹⁾

Market Cap (as of 5/9/18) \$2.2B



(1) Midpoint of guidance range communicated on 5/9/18. The fact that we include these projections in this fact sheet should not be taken to mean that these amounts continue to be our projections as of any subsequent date.

2018 Strategic Priorities for Growth



U.S. Headquarters

Wright Medical Group N.V.
1023 Cherry Road / Memphis, TN 38117
901.867.9971 / 800.238.7117

Worldwide Headquarters

Wright Medical Group N.V.
Prins Bernhardplein 200 / 1097 JB Amsterdam
The Netherlands
+31 (20) 521 4777

Investor Relations


Julie (Tracy) Dewey
SVP, Chief Communications Officer
901.290.5817
julie.dewey@wright.com

Stock Listing
NASDAQ: WMGI


Employees
Approx. 2,400

Web Site
www.wright.com


Upper Extremities




Net Sales by Geography




Lower Extremities




Net Sales by Geography



Biologics




Net Sales by Geography



*Q4 2017 growth rates include the benefit from the extra four business selling days, which the company estimates to be approximately 4.5%.

Performance Track Record




What Sets Us Apart

Recognized Leader in Extremities and Biologics



- Largest specialized direct sales force in U.S.
- Broad extremities product portfolio
- Strong R&D pipeline and continued emphasis on medical education

2017 Financial Performance from Continuing Operations (in millions)



Geographic Extremities & Biologics Net Sales



Forward-Looking Statements

This fact sheet includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "could," "may," "will," "believe," "estimate," "continue," "guidance," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this fact sheet include, but are not limited to, statements about the company's anticipated financial results for 2018, including net sales from continuing operations, adjusted EBITDA from continuing operations and adjusted earnings per share from continuing operations, anticipated strong shoulder sales growth in 2018, and anticipated U.S. lower extremities improvement in 2018 and the company's need for additional capital. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this fact sheet is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the failure of the company's 2017 U.S. sales force additions to achieve expected results, focus on core product portfolio and incentives to drive U.S. lower extremities and biologics sales or delay in realization thereof; the risk of continued supply constraints; the failure to integrate the legacy Wright and Tornier businesses and realize net sales synergies and cost savings from the merger with Tornier or delay in realization thereof; operating costs and business disruption as a result of the merger, including adverse effects on employee retention and sales force productivity and on business relationships with third parties; integration costs; actual or contingent liabilities; adverse effects of diverting resources and attention to providing transition services to the purchaser of the large joints business; the adequacy of the company's capital resources and need for additional financing; the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure to achieve the anticipated commercial sales of our AUGMENT[®] Bone Graft products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims and product recalls; pending and threatened litigation; risks associated with the metal-on-metal master settlement agreement and the settlement agreement with the three settling insurers; risks associated with the subsequent metal-on-metal settlement agreements and ability to obtain the additional new insurance proceeds contingent thereon; risks associated with international operations and expansion; fluctuations in foreign currency exchange rates; other business effects, including the effects of industry, economic or political conditions outside of the company's control; reliance on independent distributors and sales agencies; competitor activities; changes in tax and other legislation; and the risks identified under the heading "Risk Factors" in Wright's Annual Report on Form 10-K for the year ended December 31, 2017 filed by Wright with the SEC on February 27, 2018 and subsequent SEC filings by Wright, including without limitation its Quarterly Report on Form 10-Q for the quarter ended April 1, 2018. Investors should not place considerable reliance on the forward-looking statements contained in this fact sheet. Investors are encouraged to read Wright's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this fact sheet speak only as of the date of this fact sheet, and Wright undertakes no obligation to update or revise any of these statements. Wright's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Note on Non-GAAP Financial Measures


To supplement the company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, the company uses certain non-GAAP financial measures in this release. Reconciliations of the historical non-GAAP financial measures used in this fact sheet to the most comparable GAAP measures for the respective periods can be found in tables later in this release. Wright's non-GAAP financial measures include net sales, excluding the impact of foreign currency; net income, as adjusted; EBITDA, as adjusted; gross margin, as adjusted; earnings, as adjusted; and earnings, as adjusted, per diluted share, in each case, from continuing operations. The company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the company's operations, period over period. Wright's non-GAAP financial measures exclude such items as non-cash interest expense related to the company's convertible notes, transaction and transition costs, net gains and losses on mark-to-market adjustments on CVRs and derivative assets and liabilities, net non-cash gains and losses on foreign currency translation all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the company's reported results of operations for a period. It is for this reason that the company cannot provide without unreasonable effort a quantitative reconciliation to the most directly comparable GAAP measures for its 2018 financial guidance regarding non-GAAP adjusted EBITDA from continuing operations and non-GAAP adjusted earnings per share from continuing operations. Management uses the non-GAAP measures in this fact sheet internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Key Financial Statistics - Continuing Operations


	Q1 2018 ⁽¹⁾	Q1 2017 ⁽²⁾	FY 2017 ⁽³⁾
Net Sales	\$198,537	\$177,191	\$744,989
Gross Margin	\$157,398	\$140,065	\$584,042
as a percentage of net sales	79.3%	79.0%	78.4%
Non-GAAP Gross Margin As Adjusted	\$158,308	\$140,750	\$587,137
as a percentage of net sales	79.7%	79.4%	78.8%
Operating Loss	\$(890)	\$(9,598)	\$(19,691)
as a percentage of net sales	-0.4%	-5.4%	-2.6%
Non-GAAP EBITDA	\$21,750	\$3,270	\$59,967
as a percentage of net sales	11.0%	1.8%	8.0%
Non-GAAP EBITDA, As Adjusted	\$26,678	\$18,171	\$88,365
as a percentage of net sales	13.4%	10.3%	11.9%
Net Loss (cont ops)	\$(19,907)	\$(36,707)	\$(64,937)
as a percentage of net sales	-10.0%	-20.7%	-8.7%
Non-GAAP Net Loss, As Adjusted	\$(8,248)	\$(16,229)	\$(51,236)
as a percentage of net sales	-4.2%	-9.2%	-6.9%
Net Loss (cont ops) per diluted share	\$(0.19)	\$(0.35)	\$(0.62)
Adjusted non-GAAP earnings per diluted share	\$(0.01)	\$(0.09)	\$(0.22)

- (1) The Q1 2018 adjusted results exclude the after-tax effects of an unrealized gain of \$3.9 million related to mark-to-market adjustments on contingent value rights (CVRs) issued in connection with the BioMimetic acquisition, non-cash interest expense of \$12.0 million related to its convertible notes, an unrealized loss of \$1.7 million related to mark-to-market adjustments on derivatives, \$0.9 million of transaction and transition costs associated with non-cash inventory provisions, and non-cash foreign currency translation charges of \$0.8 million.
- (2) The Q1 2017 adjusted results exclude the after-tax effects of \$3.0 million of transition costs, an unrealized loss of \$0.4 million related to mark-to-market adjustments on derivatives, \$11.0 million of non-cash interest expense related to its convertible notes, and a \$6.2 million unrealized loss related to mark-to-market adjustments on contingent value rights (CVRs) issued in connection with the BioMimetic acquisition.
- (3) The full year 2017 adjusted results exclude the after-tax effects of a \$25.0 million tax benefit related to the realizability of net operating losses, a \$9.8 million benefit from incentive and indirect tax projects, an \$8.3 million tax benefit related to tax law reform in the U.S. and France, an unrealized gain of \$4.8 million related to mark-to-market adjustments on derivatives, non-cash interest expense of \$45.5 million related to its convertible notes, \$12.4 million of transaction and transition costs, and an unrealized loss of \$5.3 million related to mark-to-market adjustments on contingent value rights (CVRs) issued in connection with the BioMimetic acquisition.

Fiscal Year 2017 Sales



Global Extremities & Biologics Constant Currency Non-GAAP Growth



*Q4 2017 growth rates include the benefit from the extra four businesses selling days, which the company estimates to be approximately 4.5%.

2018 Guidance

NET SALES ⁽¹⁾	\$800M - \$812M
ADJ. EBITDA ⁽¹⁾	\$104M - \$111M

(1) Guidance range communicated on 5/9/18. The fact that we include these projections in this fact sheet should not be taken to mean that these amounts continue to be our projections as of any subsequent date.

Wright Medical:
A Global Leader on an Upward Path

POSITIONED TO OUTPERFORM

Premier
extremities/biologics company

Multiple growth drivers

Accelerated path to profitability,
stronger financial profile